Established and forthcoming drugs for the treatment of osteoporosis

Netherlands Journal of Medicine

Volumn 71, Issue 4, 2013, Pages 188-193

  Lems, W F ^a   den Heijer, M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Cathepsin K inhibitor; Denosumab; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CATHEPSIN K INHIBITOR; DENOSUMAB; GLUCOCORTICOID; IBANDRONIC ACID; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PLACEBO; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE NECROSIS; BREAST CANCER; CARDIOVASCULAR RISK; CELLULITIS; DRESS SYNDROME; ECZEMA; ESOPHAGUS CARCINOMA; HIP FRACTURE; HUMAN; INTESTINE ULCER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SPINE FRACTURE;

BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; OSTEOPOROSIS;

EID: 84878467635     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Anonymous. Consensus Development Conference: Prophylaxis and Treatment of Osteoporosis. Am J Med. 1994;646-50.
2. CBO Richtlijn Osteoporose en Fractuurpreventie derde herziening (2011) www.cbo.nl.
3. Lems WF, Raterman HG, van den Bergh JP, et al. Osteopenia: a diagnostic and therapeutic challenge. Curr Osteoporosis Rep. 2011:9:167-72.
4. Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011;25:585-91.
5. Gezondheidsraad - Naar een toereikende inname van vitamine D. Gezondheidsraad, 2008; publicatienr. 2008/15.
6. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2011.
7. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;29;341:c3691.
8. Heaney RP, Kopecky S, Maki KC, et al. A review of calcium supplements and cardiovascular disease risk. Adv Nutr. 2012;3:763-71.
9. Black DM, Delmas PD, Eastell R, et al. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. New Engl J Med. 2007;356:1809-22.
10. Sun K, Liu JM, Sun HX, Lu N, et al. Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies. Osteoporos Int. 2012 Oct 6.
11. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97:2272-82.
12. Toissant ND, Elder Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol. 2009;4:221-33.
13. Brennan TC, Rybchyn MS, Green W, et al. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol. 2009;157:1291-300.
14. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-68.
15. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816.
16. Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2012, Nov. Epub.
17. Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-45.
18. Siris ES, Harris ST, Eastell R, et al. Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005;20:1514-24.
19. Lems WF, Hamdy NAT, Netelenbos JC. Teriparatide: an anabolic drug for the treatment of patients with osteoporosis. Ned Tijdschr Geneeskd. 2006;150:132-7.
20. Moester MJ, Papapoulos SE, Lowik CW, et al. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010;87:99-107.
21. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
22. Greenspan SL, Bone HG, Ettinger MP, et al. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146,326-9.
23. Langdahl BL, Rajzbaum G, Jakob F, et al. Reduction in fracture rate and back pain and quality of life in postmenopausal women treated with teriparatide: 18 month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int. 2009;85:484-93.
24. Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality. Editorial, Arthritis Rheum. 2007;56:3518-22.
25. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-sixmonth results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346-55.
26. Sambrook PN. Anabolic therapy in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2048-6.
27. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-42.
28. Cummings SR, San Martin J, McClung M, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med. 2009;361:756-65.
29. Khosla S. Increasing options for the treatment of osteoporosis. New Engl J Med. 2009;361:818-20.
30. Papapoulos S, Chapurlat R., Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Min Res. 2012;694-701.
31. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in RA. Arthritis Rheum. 2008;58:1299-309.
32. Boonen S, Rosenberg E, Claessens F, et al. Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep. 2012;10:73-9.
33. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25;937-47.
34. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276-87.
35. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. Bone Miner Res. 2011;26:19-26.